Science Current Events | Science News | Brightsurf.com
 

Recent Hepatology Current Events

Recent Hepatology Current Events - the latest Hepatology news stories, articles, research and discoveries.
Sort By: Hepatology Current Events (Best Match) | Most Viewed Hepatology Current Events

Use of direct-antiviral agents helps overcome hepatitis C recurrence in liver transplant patients
New data presented today at The International Liver Congress™ 2015, supports the use of sofosbuvir (SOF)- and daclatasvir (DCV)-based regimens in patients with recurrence of the hepatitis C virus (HCV) following liver transplantation (LT). View News Article (2015-04-27)


Sofosbuvir + peginterferon/ribavirin demonstrates virologic response rates in G3 hep C patients
Results presented today at The International Liver Congress™ 2015 demonstrate that hepatitis C (HCV)-infected genotype-3 (GT-3) patients, with and without cirrhosis, receiving 24 weeks of sofosbuvir (SOF) in combination with ribavirin (RBV) and peginterferon (PEG) achieved the highest sustained virologic response rates at 12 weeks (SVR12), observed in a Phase 3 study, to date. View News Article (2015-04-27)


Alcohol use disorders - stronger predictor of mortality than chronic hepatitis C virus infectio
Results presented today at The International Liver Congress™ 2015, show that alcohol use disorders (AUD) have a serious, negative prognostic outcome with higher mortality risks in the general population and patients with hepatitis C virus (HCV) infection in particular.  View News Article (2015-04-27)


Drinking just 1 or 2 alcoholic drinks a day linked to liver disease
According to the World Health Organization, excessive alcohol drinking is the most common cause of cirrhosis worldwide. View News Article (2015-04-27)


Preliminary safety findings: IFN-free DAA combination in chronic HCV patients
Preliminary data from an ongoing study revealed today at The International Liver Congress™ 2015 suggest that a combination of three direct-acting antivirals (DAAs) is well tolerated in patients with severe renal impairment or end-stage renal disease when used either with or without ribavirin. View News Article (2015-04-27)


Researchers highlight need for better evidence to guide EU efforts to increase hep B+C testing
The apparent dearth of research on hepatitis B and C testing in many European countries could be hampering efforts to identify infected individuals, according to results from a comprehensive review of 136 studies presented today at The International Liver CongressTM 2015. View News Article (2015-04-27)


Use of pocket-sized ultrasound device reduces need for further testing in clinical settings
Results from a study presented today at The International Liver Congress™ 2015 demonstrate that the use of a pocket-sized ultrasound device (PUD) helps to reduce the need for further testing in both the inpatient and outpatient setting.  View News Article (2015-04-27)


Hepatitis C screening essential to help catch patients with advanced liver fibrosis
Study results presented today at The International Liver Congress™ 2015 show that the occurrence of advanced liver fibrosis is similar for patients infected with the hepatitis C virus (HCV), whether or not they have been diagnosed.  View News Article (2015-04-27)


Once-daily grazoprevir/elbasvir is effective in patients infected with chronic hepatitis C
esults presented today at The International Liver Congress™ 2015 show that a 12-week oral regimen of once-daily single tablet grazoprevir/elbasvir (GZR/EBR) is effective and well-tolerated in treatment-naive (TN) patients infected with chronic hepatitis C virus (HCV) genotypes (GT)-1, -4 or -6, including those with compensated cirrhosis.  View News Article (2015-04-24)


Ledipasvir-sofosbuvir combination proves effective in subset of patients with chronic hepatitis C
A new study presented today at The International Liver Congress™ 2015 has demonstrated that ledipasvir (LDV) in combination with sofosbuvir (SOF) achieves sustained virologic response rates 12 weeks after treatment (SVR12; primary endpoint), of 93% and 95% in patients chronically infected with hepatitis C virus (HCV) genotypes 4 or 5, respectively.  View News Article (2015-04-24)

Sort By: Hepatology Current Events (Best Match) | Most Viewed Hepatology Current Events
© 2015 BrightSurf.com